Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

Clinical trial NCT05446870 · COMPLETED

Trial details

NCT number: NCT05446870
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

High-grade Serous Ovarian Carcinoma Ovarian Carcinoma

Start date: 2022-07-25
Primary completion: 2023-12-20
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.